Current Report Filing (8-k)
June 15 2018 - 6:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 14, 2018
BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34236
|
11-3054851
|
(State or Other Jurisdiction
|
(Commission File Number)
|
(I.R.S. Employer
|
Of Incorporation)
|
|
Identification No.)
|
35 Wilbur Street
Lynbrook, NY 11563
(Address of Principal Executive Office) (Zip Code)
516.593.7000
(Registrants telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934.
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [ ]
INTRODUCTORY COMMENT
Throughout this Current Report on Form 8-K, the terms
we, us, our and Company refer to BioSpecifics Technologies Corp.
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS
The 2018 annual meeting of stockholders of the Company (the
2018 Annual Meeting) was held on June 14, 2018. At the 2018 Annual Meeting,
the holders of 7,199,233 shares of the Companys common stock were represented
in person or by proxy, thereby constituting a quorum.
Set forth below are the final voting results for each of the
matters submitted to a vote of the stockholders of the Company at the 2018
Annual Meeting.
Proposal 1.
The stockholders of the Company elected
Thomas Wegman and Dr. Paul Gitman to the Board of Directors, each to serve until
the 2021 annual meeting of stockholders or until such person resigns, is
removed, or otherwise leaves office. The votes were cast as follows:
Director Name
|
For
|
Withheld
|
Thomas Wegman
|
3,126,419
|
1,976,127
|
Dr. Paul Gitman
|
2,626,733
|
2,475,913
|
Proposal 2.
The stockholders of the Company approved, on
an advisory basis, the Companys named executive officer compensation as
disclosed in the Companys proxy statement filed with the Securities and
Exchange Commission on April 30, 2018.
For
|
Against
|
Abstain
|
5,076,481
|
21,445
|
4,720
|
Proposal 3.
The stockholders of the Company approved the
ratification of the appointment of EisnerAmper LLP as the Companys independent
registered public accounting firm for the fiscal year ending December 31, 2018.
The votes were cast as follows:
For
|
Against
|
Abstain
|
6,798,318
|
2,108
|
1,868
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: June 14, 2018
|
BIOSPECIFICS TECHNOLOGIES CORP.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
/s/Thomas L. Wegman
|
|
|
|
Thomas L. Wegman
|
|
President
|
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Apr 2023 to Apr 2024